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Abstract
Target-specific treatment modalities are currently not available for triple-negative breast cancer (TNBC), and acquired
chemotherapy resistance is a primary obstacle for the treatment of these tumors. Here we employed derivatives of BT-
549 andMDA-MB-468 TNBC cell lines that were adapted to grow in the presence of either 5-Fluorouracil, Doxorubicin or
Docetaxel in an aim to identify molecular pathways involved in the adaptation to drug-induced cell killing. All six drug-
adapted BT-549 and MDA-MB-468 cell lines displayed cross resistance to chemotherapy and decreased apoptosis
sensitivity. Expression of the anti-apoptotic co-chaperone BAG3 was notably enhanced in two thirds (4/6) of the six
resistant lines simultaneously with higher expression of HSP70 in comparison to parental controls. Doxorubicin-resistant
BT-549 (BT-549rDOX20) and 5-Fluorouracil-resistantMDA-MB-468 (MDA-MB-468r5-FU2000) cellswere chosen for further
analysis with the autophagy inhibitor Bafilomycin A1 and lentiviral depletion of ATG5, indicating that enhanced
cytoprotective autophagy partially contributes to increased drug resistance and cell survival. Stable lentiviral BAG3
depletionwas associatedwith a robust down-regulation ofMcl-1, Bcl-2 andBcl-xL, restoration of drug-induced apoptosis
and reduced cell adhesion in these cells, and these death-sensitizing effects could be mimicked with the BAG3/Hsp70
interaction inhibitor YM-1 and by KRIBB11, a selective transcriptional inhibitor of HSF-1. Furthermore, BAG3 depletion
was able to revert the EMT-like transcriptional changes observed in BT-549rDOX20 and MDA-MB-468r5-FU2000 cells. In
summary, genetic and pharmacological interference with BAG3 is capable to resensitize TNBC cells to treatment,
underscoring its relevance for cell death resistance and as a target to overcome therapy resistance of breast cancer.
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Despite advances in screening techniques leading to early detection of
breast cancer, resistance to tumor therapy is still a major challenge in
treatment of this disease, and recurrence rates are very high [1,2].
Drug resistance is broadly classified into two types; 1) de novo
(intrinsic) drug resistance in patients that do not respond to
conventional therapies, and 2) acquired resistance in patients
developed during treatment [3]. Intrinsic and acquired therapy
resistances are major challenges for the successful treatment of
patients, in particular those with triple-negative breast cancer
(TNBC) [4]. TNBC is a subtype of epithelial breast cancer that
doesn’t express estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor 2 (HER2) [5]. Only
15-20% of the total population of breast cancers is triple negative, but
these are highly aggressive and metastatic. Due to the absence of
specific therapeutic targets, treatment strategies against this tumor
subtype are severely limited. As a consequence, current treatment of
these tumors is restricted to chemotherapy, frequently leading to
development of therapy resistance and recurrent disease [6]. Acquired
drug resistance of tumor cells can be driven by a plethora of different
mechanisms, like increased drug efflux, tumor cell heterogeneity,
inactivation of apoptosis, increased DNA repair, angiogenesis, altered
metabolism and stress-induced genetic or epigenetic alterations after
drug exposure [3,7–11]. Among these mechanisms, the adaptation of
cancer cells to different cellular stress conditions (as induced by
anti-cancer drugs) play a particularly important role for therapy
resistance. A better understanding of the underlying resistance
mechanisms are urgently required to identify new targets for
treatment in an aim to improve clinical outcomes of TNBC.
Resistance to cell death caused by defects in apoptotic pathways and
overexpression of anti-apoptotic proteins is a general hallmark of cancer
[12–14]. Pro- and anti-apoptotic members of the Bcl-2 family are key
regulators of apoptotic cell death. The Bcl-2 family proteins can be
classified into three subfamilies: (i) the pro-apoptotic BH3-only proteins
which have only one domain in common, the alpha helical BH3 domain;
(ii) the pro-apoptotic Bax-like proteins which contain three such domains
(BH1,2,3) and (iii) the anti-apoptotic Bcl-2-like proteins that contain 4
homology domains (BH1-4) and are regularly overexpressed in cancer.
Bax and Bak trigger mitochondrial outer membrane permeabilization
(MOMP) that is required for the release of pro-apoptotic factors from the
mitochondria into the cytosol. This intrinsic apoptosis pathway is kept in
check by the pro-survival Bcl-2 family members (Bcl-2, Bcl-xL, Mcl-1,
Bcl-w and Bfl-1) [15–17].
The Hsp70 co-chaperone and anti-apoptotic protein BAG3 (also
called Bis) is a member of the Bcl-2-associated anthanogene (BAG)
protein family. This highly conserved family of co-chaperone interacts
with the ATPase domain of heat shock protein 70 (HSP70) through a
specific structural domain – the BAG domain [18]. BAG3 regulates
several key hallmarks of cancer, including cell survival, cell adhesion,
metastasis, angiogenesis and regulation of proteostasis [19,20]. A key
mechanism promoting its anti-apoptotic function is represented by
BAG3-dependent stabilization of the pro-survival Bcl-2 family
members including Bcl-2, Bcl-xL and Mcl-1, thereby supporting
the anti-apoptotic function of these proteins [21,22]. BAG3
expression has been reported to be elevated in various tumors
including breast cancer, and we could previously show that estrogen
receptor α (ERα) regulates a non-canonical type of autophagy that
involves the function of BAG3 and provides stress resistance in
ERα-expressing breast cancer cells [23].
Here we investigated the cellular mechanisms promoting enhanced
chemotherapy resistance in TNBC cells adapted to growth in the
presence of the clinically relevant chemotherapeutic agents
5-Flourouracil (5-FU), Doxorubicin (DOX) and Docetaxel (DOC).
We demonstrate that increased apoptosis resistance is associated with
enhanced cytoprotective autophagy, elevated expression of the
oncogenic co-chaperone BAG3, BAG3-dependent stabilization of
pro-survival Bcl-2 proteins and induction of EMT-like changes in
gene expression. We also show that genetic and pharmacological
interference with BAG3 function is capable to resensitize cells to
apoptosis, underscoring the relevance of BAG3 as a target to
overcome therapy resistance in TNBC.
Materials and Methods
Materials
Staurosporine (STS) was obtained from Alexis Biochemicals (San
Diego, CA, USA). KRIBB11 ((N(2)-(1H-indazole-5-yl)-N(6)-
methyl-3-nitropyridine-2,6-diamine)) was acquired from Calbiochem
(Darmstadt, Germany). Bafilomycin A1 (Baf A1), YM-1
(2-((Z)-((E)-3-Ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-ox-
othiazolidin-2-ylidene)methyl)-1-methylpyridin-1-ium chloride),
p-HEMA (Poly (2-hydroxyethyl methacrylate)), Doxorubicin
hydrochloride (DOX), Docetaxel (DOC), 5-Fluorouracil (5-FU),
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium (MTT),
ABT-737 and all other chemicals or biochemicals were purchased
from Sigma-Aldrich (Munich, Germany).
Cell lines and Culture
The triple negative parental human breast cancer cell lines BT-549
and MDA-MB-468 were obtained from ATCC/LGC Promochem
GmbH (Wesel, Germany). The chemoresistant cell lines were
established by continuous exposure to increasing concentrations of
the respective drugs to the parental cell lines as previously described
[24,25] and derived from the Resistant Cancer Cell Line (RCCL)
collection (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html).
5-Fluorouracil (5-FU) resistant BT-549 and MDA-MB-468 sublines
were cultured under continuous presence of 2000 ng/ml of 5-FU and
named as BT-549 r5-FU2000 and MDA-MB-468 r5-FU2000 respec-
tively, BT-549 and MDA-MB-468 cell lines were adapted to 40 ng/
ml and 20 ng/ml of Docetaxel (DOC) and named as
BT-549 rDOC40 and MDA-MB-468 rDOC20respectively, whereas
Doxorubicin (DOX) resistant BT-549 and MDA-MB-468 cell lines
were cultivated under the presence of 20 ng/ml and 200 ng/ml of
DOX and named as BT-549 rDOX20 and MDA-MB-468 rDOX200
respectively. BT-549 parental and chemoresistant cells were cultured
in Iscove modified Dulbecco’s medium (IMDM) supplemented with
10% Fetal Calf Serum (FCS), 4 mM L-glutamine, 10*2 IU/ml
penicillin and 100 μg/ml streptomycin, whereas MDA-MB-468
parental and chemoresistant cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) with F-12 Nutrient Mixture (Ham)
supplemented with 10% FCS, 4 mM L-glutamine, 20 mM HEPES,
10*2 IU/ml penicillin and 100 μg/ml streptomycin (all: Gibco/
Invitrogen, Karlsruhe, Germany) and cultures were maintained in a
humidified 37°C and 5% CO2 incubator.
Lentiviral Transduction
Lentiviral vector stocks specific for BAG3 (SHCLNV-NM_
004281; TRCN0000007294; Sigma-Aldrich) and ATG5
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(SHCLNG-NM_004849; TRCN0000151474; Sigma-Aldrich) were
used for transduction of both the parental and resistant cell lines of
BT-549 and MDA-MB-468 breast cancer cells. Five different small
hairpins sequences were included to set the target. (SHC002;
Sigma-Aldrich), the pLKO.1-puro Non-Mammalian shRNA control
plasmid DNA was used as a negative control. Transduction was
executed as previously reported [26].
Cell Viability (MTT) Assay
3,000 cells suspended in 100 μl of medium were seeded per well in
96-well-plates and cultured for 24 h before onset of treatment. After
completion of the treatment period, 20 μ l of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
from 5 mg/ml of stock solution were added into 100 μl of medium
in each well, followed by 3 h of incubation in a humidified 37°C and
5% CO2 incubator. Following 3 h of incubation, the medium
containing MTT reagent was discarded, the formazan crystals formed
after MTT treatment were solubilized by adding 100 μl of the
mixture of isopropanol/1M HCl (24:1) and gently shaken for 30 min
in dark condition. Then absorbance was measured at 560 nm using
microplate reader (TECAN GENios, Crailsheim, Germany).
Flow Cytometry
For quantitative estimation of cell death, flow cytometry was
performed as previously described [26].
SDS-PAGE and Western Blotting
SDS-PAGE and Western blotting were performed as recently
reported [27]. After blocking in 5% BSA for 1 h at room temperature,
the nitrocellulose membranes were incubated overnight at 4°C with
primary antibodies directed against BAG3 (rabbit, 1:5000, Abnova,
Heidelberg, Germany), LC3 (rabbit, 1:1000, Thermo Fisher
Scientific, Rockford, USA), p62 (mouse, 1:1000, BD Biosciences,
USA), GAPDH (mouse, 1:10,000, Calbiochem) and rest were
against Bcl-2, Mcl-1, Bcl-xL, HSP70, HSF-1, Bak, Bax, ATG5,
Beclin-1, pFAK (Tyr397), FAK, HSP60, E-cadherin and N-cadherin
which were purchased from Cell Signaling Technology (Danvers,
USA) raised in rabbit and used in the dilution of 1:1000. Following
incubation, primary antibodies were detected by using respective
secondary antibodies coupled with infrared dyes in green (800 CW)
or red (680 RD) (IRDye goat anti-rabbit or anti-mouse from LICOR
Biosciences, Bad Homburg, Germany diluted in 1:10,000 in 3% BSA
for 1 h at room temperature and the signals were detected using the
LI-COR Odyssey Infrared Imager (LI-COR Biosciences, Bad
Homburg, Germany).
Confocal Microscopy
Cells seeded on chamber slide were fixed with paraformaldehyde
(4% PFA) after completion of the respective treatments and
permeabilized with 0.1% Triton X-100. For assessment of Cellular
morphology, cells were stained with Texas Red-X phalloidin
(ThermoFisher Scientific, Darmstadt, Germany). DAPI (Applichem,
Darmstadt, Germany) was used for nuclear staining in all cases. After
mounting on microscope slides, cells were finally analyzed using
Nikon C1i confocal microscope.
Quantitative Real-Time PCR
Total RNA isolation and quantitative real-time PCR (qPCR) was
executed as previously described [28]. The StepOnePlus™ Real-Time
PCR System (Life Technologies, Darmstadt, Germany) was used for
the detection of fluorescence signal above the threshold (Ct) value
followed by normalization of fluorescence intensity of the samples
were performed to the amplification value of the control gene TATA
box binding protein (TBP). All the primers for qPCR were purchased
from Applied Biosystems (Darmstadt, Germany). Following primers
were used for qPCR: TaqMan® Gene Expression Assay primer for
BAG3(Hs00188713_m1), CDH1 (Hs01023895_m1), CDH2
( H s 0 0 1 6 9 9 5 3 _m 1 ) , SN A I 1 ( H s 0 0 1 9 5 5 9 1 _m 1 ) ,
SNAI2(Hs00161904_m1), TWIST1(Hs01675818_S1), TWIST2
(Hs02379973_s1).
poly-HEMA Coating for Suspension Cultures
poly-HEMA (p-HEMA) solution was prepared by suspending
1mg of p-HEMA powder in 1 ml of 95% of ethanol followed by
thorough mixing at 50°C and 750 rpm in Thermomixer comfort
(Eppendorf) for overnight. Then the homogenized solution was
filtered and pipetted into 24 well plates and allowed to dry inside the
safety hood for two days with opened lids. Before the cells were
seeded, the wells were properly washed with sterile PBS and finally the
cells were allowed to remain in suspension condition throughout the
experiment.
Invasion (Boyden-Chamber) Assay
Before seeding the cells into the chamber, the matrigel (Corning
transwell insert with 8 μm pore, Corning, Tewksbury, MA) was
rehydrated with 500 μl of FCS-free medium for 2 hours inside the
humidified 37°C and 5% CO2 incubator. Then approximately 750
μl of medium containing 10% FCS was added into the wells of the
24-well cell culture insert companion plate. After discarding the
rehydration medium, the transwell inserts were put into the wells of
the cell cultured insert companion plate carefully by avoiding air
bubble. Then approximately 20,000 cells suspended in 500 μl
medium containing 2% FCS were seeded into the matrigel coated
insert. After 20 hours of incubation, the cells on the top of the inserts
were removed by using Q-tips and the cells attached to the bottom of
the inserts were fixed with methanol for 2 minutes followed by
staining for another 2 minutes with 0.1% crystal violate. The
chambers were washed three four times in purified water and allowed
to air dry. Then 6 pictures of each matrigel were captured with a
Nikon TS100 inverted microscope equipped with a charge-coupled
device (CCD) camera followed by counting of stained cells by using
ImageJ software. Three matrigel chambers were used for each
condition and each experiment was repeated 3 times.
Migration (Scratch) Assay
400,000 cells were seeded per well in 6 well cultured plates. After
24 hours of incubation, 10 μg/ml of Mitomycin C (Sigma-Aldrich)
was added for 2 hours to prevent cell proliferation. Then a scratch was
made using 200 μl pipette tip followed by washing with PBS. Pictures
of the scratch at 0 hour time point were taken and the same positions
were captured after 20 hours of incubation. The number of cells
migrated into the scratch area were counted using ImageJ software.
Each experiment was repeated for 3 times.
Subcellular Fractionation
The digitonin-based subcellular fractionation technique was
employed for the separation of cytosolic and mitochondrial fractions
as previously described [29].
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Global Proteomics Analysis
For global proteomic analysis, the cells were grown until ~70%
confluency. For each cell line, three independent samples were taken.
Samples for LC-MS/MS analysis were prepared according to Kulak et
al. with minor modifications [30]. In brief, cell lysis and protein
denaturation were performed by boiling the samples in 6 M GnHCl,
100 mM Tris pH 8.5, 10 mM TCEP and 40 mM ChlAA. Proteins
were digested with Lys-C for 3 hours, followed by tryptic digestion
overnight. Tryptic peptides were desalted and concentrated using
STAGE-Tips (Empore C18, 3M).
Peptides were separated on an easy nLC 1200 (ThermoFisher
Scientific) and a 15 cm long, 75μm ID fused-silica column, which has
been packed in house with 1.9 μm C18 particles (Dr. Maisch), and
kept at 45°C using an integrated column oven (Sonation). Peptides
were eluted by a non-linear gradient from 4% to 48% acetonitrile
over 135 minutes and directly sprayed into a QExactive HF
mass-spectrometer equipped with a nanoFlex ion source (Thermo-
Fisher Scientific). Precursor ions were analyzed with a resolution of
60,000 and the 15 most abundant ions were subjected to HCD
fragmentation and resulting fragments were analyzed with a
resolution of 15,000. Single charged ions and ions with unassigned
charge states were not taken into account for fragmentation and
dynamic exclusion was set to 20 s.
Data analysis was done with MaxQuant and essentially default
settings [31]. Fragment spectra were searched against the Uniprot
human reference proteome (version “December 2017”), with a false
discovery rate of 1% on PSM and protein level and at least one unique
peptide. Fold changes were determined by LFQ quantification with
the “match between runs”-option being activated [32]. Statistical
significant changes between parental and resistant cell-lines were
determined with Perseus using a Two-sample t-test with a
permutation based FDR of 5% and a s0 of 0.6 on log2 transformed
LFQ values [33].
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium (http://proteomecentral.proteomex-
change.org) via the PRIDE partner repository with the dataset
identifier PXD008522 [34]. ProteomeXchange provides globally
co-ordinate proteomics data submission and dissemination [34].
Statistics
Data are represented as means ± SEM. For statistical analysis, t-test
(two-tailed) was applied by using (GraphPad Prism, GraphPad
Software, Inc., La Jolla, CA, USA). pb0.05 was considered to be
statistically significant and was denoted with asterisks or hashtags.
Results
BAG3 is Overexpressed in Chemoresistant Breast Cancer Cells
In our study, the triple negative breast cancer cell line BT-549 was
adapted to growth in medium containing either 2000 ng/ml of 5-FU,
40 ng/ml of DOC or 20 ng/ml of DOX; the MDA-MB-468 cell line
was similarly adapted to growth in the presence of 2000 ng/ml of
5-FU, 20 ng/ml of DOC or 200 ng/ml of DOX. The 50% inhibitory
concentration (IC50) value of each drug was obtained by MTT assays.
Table 1 depicts the IC50 value of each drug and the level of cross
resistance of the BT-549Par (parental control cells), BT-549 r5-
FU2000 (adapted to 5-Fluorouracil), BT-549 rDOC40 (adapted to
Docetaxel), BT-549 rDOX20 (adapted to Doxorubicin), MDA-MB-
468Par (parental control cells), MDA-MB-468 r5-FU2000 (adapted to
5-Fluorouracil), MDA-MB-468 rDOC20 (adapted to Docetaxel), and
MDA-MB-468 rDOX200 (adapted to Doxorubicin) cell lines to the
chemotherapeutic drugs 5-FU, DOC and DOX. All drug-adapted
cell lines displayed increased resistance to the other two chemother-
apeutic agents at a varying degree. Further we used staurosporine
(STS), a well-recognized apoptotic cell death inducer to investigate
the possible changes in the general sensitivity to apoptosis in
chemoresistant cell lines and analyzed early apoptosis and total cell
death by FACS-based Annexin V/PI-staining. FACS data (Figure 1A)
revealed that all drug-adapted BT-549 and MDA-MB-468 cell lines
are significantly more resistant to STS compared to their parental
counterparts, indicating decreased apoptosis sensitivity. Expression
analysis of anti-apoptotic and pro-apoptotic Bcl-2 family members by
western blot unveiled a prominent increase of Bcl-2, Bcl-xL and Mcl-
1 proteins in BT-549 rDOX20 and MDA-MB-468 r5-FU2000 cells
whereas Bak and Bax expression is decreased in almost all the resistant
cells compared to their parental controls (Figure 1B). Since we found
an increased expression of anti-apoptotic Bcl-2 family proteins in
chemoresistant BT-549 rDOX20 and MDA-MB-468 r5-FU2000 cells,
we also treated these cells with the selective BH3-mimetic ABT-737 to
determine whether the drug resistant cells are sensitive to inhibition of
Bcl-2 and Bcl-xL. Interestingly, our cell viability assay indicates that
both the resistant lines are sensitive to ABT-737, with an increased
sensitivity of MDA-MB-468 r5-FU2000 cells in comparison to
control cells (Figure S1). Further, we investigated the expression
Table 1. Establishment of Breast Cancer Cellular Resistant Models
IC50 ± SEM BT-549
Par r5-FU rDOC rDOX
5-Fluorouracil (μg/ml) 0.63 ± 0.21 5.89 ± 0.47 4.24 ± 1.39 3.37 ± 0.13
Docetaxel (ng/ml) 8.12 ± 0.84 12.82 ± 1.67 212.56 ± 1.20 37.09 ± 2.18
Doxorubicin (ng/ml) 9.46 ± 1.62 15.97 ± 1.26 180.6 ± 2.09 84.38 ± 1.92
IC50 ± SEM MDA-MB-468
Par r5-FU rDOC rDOX
5-Fluorouracil (μg/ml) 1.16 ± 0.14 18.97 ± 0.29 5.97 ± 0.07 4.28 ± 0.83
Docetaxel (ng/ml) 9.74 ± 1.02 12. 62 ± 0.86 63.07 ± 1.93 13.47 ± 0.32
Doxorubicin (ng/ml) 116 ± 1.69 129.20 ± 1.95 338.47 ± 1.40 536.47 ± 1.79
Breast cancer cell line BT-549 was adapted to grow isolatedly with 2000 ng/ml of 5-FU, 40 ng/ml of DOC and 20 ng/ml of DOX; MDA-MB-468 cell line was grown similarly with 2000 ng/ml of 5-FU,
20 ng/ml of DOC and 200 ng/ml of DOX. Then 50% inhibitory concentration (IC50) value of each drug was determined by MTT assay. The values are means of three independent experiments
performed in triplicate ± SEM. p valuesb0.05 were considered to be statistically significant.
266 BAG3 and Cytoprotective Autophagy in Chemoresistant Breast Cancer Cells Das et al. Neoplasia Vol. 20, No. 3, 2018
levels ofHSP70 andBAG3, aHSP70 co-chaperone in all the parental and
chemoresistant cells.Western blot analysis revealed a pronounced increase
of BAG3 and HSP70 in most of the chemoresistant cell lines, with
BT-549rDOX20 (Figure 1C) andMDA-MB-468r5-FU2000 (Figure 1D)
cells showing the highest expression compared to their parental control
cells, respectively.
Attenuation of Autophagy Increases the Sensitivity of Che-
moresistant Breast Cancer Cells
One of the potential mechanisms contributing to cell survival in
chemoresistance is increased autophagy [35]. To further investigate
this possibility in our cell models, we explored the basal autophagy
status in all the parental and chemoresistant cells as a starting point.
Figure 1. Overexpression of BAG3, HSP70 and other anti-apoptotic proteins and down-regulation of pro-apoptotic proteins in
chemoresistant breast cancer cells. (A) BT-549 andMDA-MB-468 parental and chemoresistant cell lineswere treatedwith 3 μMof apoptotic
cell death inducer staurosporine (STS) andDMSO (0.1%) as control for 6 hours followedby%of total cell death and%ofAnnexin-V positive &
PI negative cells were estimated by flow cytometry. Data are representative of three independent experiments performed in triplicate.
Columns represent means ± SEM. Statistical significance; *pb0.05, ** pb0.01, *** pb0.001 and ns not significant compared to controls
(DMSO). (B)Western blot analysis showsanti-apoptotic proteins (Bcl-2, Bcl-xL, andMcl-1) are over expressedandpro-apoptotic proteins (Bax
and Bak) are down regulated in chemoresistant cell lines compared to the parental counterparts. (C) BAG3 and (D) HSP70 are highly
expressed in various chemoresistant cell lines. GAPDH was used as loading control. Densitometric analysis of relative BAG3 protein
expressionwas performed in BT-549 andMDA-MB-468 parental and chemoresistant cell lines. Columns representmeans±SEM. Statistical
significance; ** pb0.01, *** pb0.001 compared to parental control cells.
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Most of the chemoresistant cells exhibited slightly enhanced levels of
autophagy marker proteins like LC3-II, ATG5 and Beclin-1
compared to their parental controls, with the most pronounced
changes observed in BT-549 rDOX20 and MDA-MB-468 r5-FU2000
cells (Figure 2A) that were chosen for a subsequent, more detailed
analysis. Western blot analysis revealed a shift from LC3-I to LC3-II
and accumulation of p62 after combined treatment with Bafilomycin
A1 and the respective drugs, i.e. DOX in BT-549Par and
BT-549 rDOX20 cells (Figure 2B), and 5-FU in MDA-MB-468Par
and MDA-MB-468 r5-FU2000 cells (Figure 2C). The LC3 shift and
accumulation of p62 appeared to be more prevalent in the
chemoresistant cells, suggesting that the autophagic flux may be
increased in these cells compared to parental controls. The effect of
autophagy is highly context-dependent and it can promote either cell
survival or cell death [36]. In order to evaluate the death-modulating
role of autophagy in our chemoresistant cells, a combined treatment
of Bafilomycin A1 and the chemotherapeutic drugs was performed.
BT-549 cells were treated with 10 ng/ml of DOX (approximate IC50
of BT-549Par) and 80 ng/ml of DOX (approximate IC50 of BT-
549 rDOX20), MDA-MB-468 cells were treated with 1 μg/ml of 5-
FU (approximate IC50 of MDA-MB-468Par), and 18 μg/ml of 5-FU
(approximate IC50 of MDA-MB-468
r5-FU2000) (see Table 1). Then
total cell death was assessed by FACS analysis. FACS data revealed a
significant increase of total cell death in BT-549 rDOX20 (Figure 2D)
and MDA-MB-468 r5-FU2000 cells (Figure 2E) after combined
treatment with chemotherapeutics and Bafilomycin A1, whereas the
amount of cell death in parental cells remained largely unaltered. We
also genetically inhibited autophagy by a stable lentiviral ATG5
knockdown (ATG5 KD). ATG5 is a key molecule in the early stage of
autophagosome formation [37] and depletion of ATG5 is an efficient
way to interfere with induction of macroautophagy. Stable ATG5
knockdowns were established both in the BT-549par and BT-549
Figure 2. Induction of prosurvival autophagy in chemoresistant cells and pharmacological inhibition of autophagy augments the
sensitivity of chemoresistant breast cancer cells (A) Basal level of autophagy was increased in chemoresistant cells as LC3-II, ATG5 and
Beclin-1 proteins expression were increased in chemoresistant cells compared to their respective parental cells in western blot analysis.
(B) Autophagic flux was determined by the accumulation of LC3-II and p62 after combined treatment of DOX (10 ng/ml) for 72 h and
autophagic flux inhibitor Baf A1 (25 nM) for 4 h in both the BT-549Par and BT-549rDOX20 cells and (C) similarly in MDA-MB-468Par and
MDA-MB-468r5-FU2000 cell lines after combined treatment of 5-FU (1 μg/ml) for 72 h and Baf A1 (25 nM) for 4 h. GAPDH was used as
loading control. (D) Breast cancer cell lines BT-549Par and BT-549rDOX20were treated with 10 ng/ml and 80 ng/ml of DOX for 72 h with or
without Baf A1 (25 nM for 4 h), (E) similarly MDA-MB-468Par andMDA-MB-468r5-FU2000 cell lines were treated with 1 μg/ml and 18 μg/ml
of 5-FU for 72 h with or without Baf A1 (25 nM for 4 h). Total cell death was quantified by Annexin V/PI double staining followed by flow
cytometry. Columns represent means of three independent experiments performed in triplicate ± SEM. Statistical significance: * pb0.05,
** pb0.01, *** pb0.001 and ns not significant compared to respective controls (Ctrls); # pb0.05, ## pb0.01 and ns not significant with Baf
A1 treatment compared to without Baf A1 treatment.
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rDOX20 cells (Figure 3A), as well as in MDA-MB-468Par and
MDA-MB-468 r5-FU2000 cells (Figure 3B). Knockdown of ATG5
decreased the LC3-II level in BT-549 rDOX20 (Figure 3A) and
MDA-MB-468 r5-FU2000 (Figure 3B) cells. Further, we found a
decrease in the expression of Mcl-1 and Bcl-2 proteins following
knockdown of ATG5 in BT-549 rDOX20cells (Figure 3C) and also in
MDA-MB-468 r5-FU2000 (Figure 3D) cells. For assessment of cell
death after ATG5 KD, we performed a dose escalation experiment
with DOX for 72 h in the BT-549Par/sh Ctrl, BT-549Par/ATG5
KD, BT-549 rDOX20/sh Ctrl and BT-549 rDOX20/ATG5 KD cells
followed by FACS analysis of total cell death. FACS data revealed a
minor, but significant increase of total cell death in the
BT-549 rDOX20/ATG5 KD cells compared to BT-549 rDOX20/sh
Ctrl, whereas the amount of cell death in BT-549par/ATG5 KD
compared to BT-549par/sh Ctrl remained unaltered (Figure 3E).
These observations confirm our previous results obtained with
pharmacological inhibition of autophagy by Bafilomycin A1.
Collectively, we conclude that increased autophagy in chemoresistant
cells acts in a cytoprotective manner and may partially contribute to
enhanced therapy resistance.
Figure 3. Knockdown of ATG5 sensitizes chemoresistant breast cancer cells (A) Stable lentiviral knockdowns of ATG5 were established in
both the BT-549Par and BT-549rDOX20 cells and (B) also in the MDA-MB-468Par and MDA-MB-468r5-FU2000 cells. Stable lentiviral
transduction of control vector was used as control (Ctrl). Knockdowns were confirmed by western blot. Knockdown of ATG5 reduced
LC3-II protein expression in BT-549rDOX20 and MDA-MB-468r5-FU2000 cells. GAPDH was used as loading control in western blot. (C)
Down regulation of ATG5 reduces the protein expression of Mcl-1 and other anti-apoptotic proteins, whereas augments the expression of
pro-apoptotic proteins likes Bak and Bax in BT-549rDOX20and (D) MDA-MB-468r5-FU2000 cells respectively. GAPDH served as loading
control in western blot. (E) BT-549rDOX20/ATG5 KD cell exhibited significantly higher levels of total cell death compared to the BT-549Par
cells after 72 hours of DOX treatment in a dose dependent manner. 0.1% DMSO for 72 h was used as control. Cell death was determined
by Annexin V/PI double staining followed by flow cytometry. Data are means ± SEM of three different experiments each performed in
triplicate. * pb0.05 ** pb0.01, *** pb0.001 and ns not significant compared to respective controls (Ctrls); # pb0.05, ## pb0.01 and ns not
significant of ATG5 KD compared to respective sh Ctrls.
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Lentiviral Depletion of BAG3 Resensitizes Chemoresistant
Breast Cancer Cells to Therapy
So far we had observed that the higher expression of BAG3 protein
is associated with simultaneously increased basal levels of autophagy
and enhanced apoptosis resistance in BT-549rDOX20 and MDA-MB-
468r5-FU2000 cells compared to their parental counterparts. BAG3 has
key functions in regulation of both autophagy and apoptosis. It maintains
cellular homeostasis by selective degradation of damaged proteins after
recruiting the macroautophagic pathway [38]. Importantly, it also
antagonizes activation of the intrinsic apoptosis pathway through
stabilization of Bcl-2 proteins [22]. To further delineate the role of
BAG3 as a resistance factor in chemoresistant cells, we established stable
lentiviral BAG3 knockdowns in the BT-549Par and BT-549rDOX20
cells (Figure 4A), and in MDA-MB-468Par and MDA-MB-
468r5-FU2000 cells (Figure 4B), confirmed by western blot and qPCR
in BT-549Par and BT-549 rDOX20 (Figure 4C), as well as
MDA-MB-468Par and MDA-MB-468r5-FU2000 (Figure 4D) cells.
The level of LC3-II was significantly decreased in the BT-549rDOX20/
BAG3 KD cells (Figure 4A) and a similar result was also obtained in
MDA-MB-468r5-FU2000/BAG3KDcells (Figure 4B).Ourwestern blot
data indicates that HSP70 and the anti-apoptotic proteins Mcl-1, Bcl-2
andBcl-xL are decreased in BT-549rDOX20/BAG3KDcells (Figure 4E)
and MDA-MB-468r5-FU2000/BAG3 KD cells (Figure 4F) to levels
comparable to those observed in parental control cells. These data suggest
that interference with BAG3 is able to effectively counteract the
chemoresistance-associated increase of Mcl-1, Bcl-2 and Bcl-xL
expression. It was previously proposed that BAG3 may also sequester
pro-apoptotic BAX in the cytoplasm and serve to inhibit itsmitochondrial
translocation in glioblastoma cells [21]. Consistent with this hypothesis,
we found that mitochondrial BAX was increased in BAG3-depleted
MDA-MB-468r5-FU2000cells (Figure S2). To analyze whether knock-
down of BAG3 KD also reactivates the sensitivity of the chemoresistant
cells to the respective drugs, we performed cell death assays following
DOX treatment in BT-549 cell lines and 5-FU treatment in
MDA-MB-468 cell lines, respectively. Indeed, our FACS data reveal
that both BT-549 rDOX 20/BAG3 KD (Figure 4G) and
MDA-MB-468r5-FU2000/BAG3 KD (Figure 4H) cells are significantly
resensitized to the respective drugs, which was not observed in parental
BAG3 KD cells compared to their controls.
Drug Resensitization by Pharmacological Interference with the
HSF1/HSP70/BAG3 Pathway
It was recently reported that BAG3 acts as a critical molecule in
HSP70-modulated cancer signaling. Thus, targeting the interaction
of these two molecules may represent a promising therapeutic strategy
[39]. For selective disruption of the HSP70/BAG3 complex, we used
YM-1 according to Colvin et al. [39]. YM-1 treatment of BT-549
rDOX20 cells dramatically reduced Mcl-1 levels in a time-dependent
manner (Figure 5A). Combined treatment with YM-1 and DOX
applied at different concentrations synergized in limiting cell viability
in BT-549 rDOX20 cells, but not in the parental BT-549 cells, as
confirmed by MTT assays (Figure 5B). Furthermore, combined
treatment of YM-1 and DOX significantly increased cell death in
BT-549 rDOX20 cells, as detected by Annexin-V staining followed by
FACS analysis (Figure 5C). Please note that in this experiment, PI
staining could not be performed due to the autofluorescence
properties of YM-1. The stress induced transcription factor heat
shock factor 1 (HSF-1) acts upstream of HSP70 and its co-chaperone
BAG3. Since BAG3/HSP70 interaction stabilizes Mcl-1, inhibition of
HSF-1 should lead to rapid degradation of Mcl-1 [22]. To further
decipher the importance of the HSF-1/HSP70/BAG3 pathway for cell
death resistance, the HSF-1 inhibitor KRIBB11 was used in comparison
to the experiments previously executed with knockdown of BAG3. The
combined treatment of KRIBB11 and DOX significantly increased
apoptosis in BT-549rDOX20/sh Ctrl cells; with overall cell death reaching
a very similar extent in comparison to BT-549rDOX20/BAG3 KD cells
treated with DOX (Figure 5D). The expression of BAG3, HSP70, and
Mcl-1 and LC3-II proteins gradually decreased in BT-549rDOX20
(Figure 5E) and MDA-MB-468r5-FU2000 cells (Figure 5F) in a
dose-dependent manner after 48 h treatment of KRIBB11.
BAG3 Depletion Alters Cell Matrix Adhesion in Chemoresis-
tant Breast Cancer Cells
It was previously reported that BAG3 significantly contributed to
maintenance of the cell adhesion properties [40]. To explore the effect
of BAG3 knockdown on cell adhesion properties of our drug-resistant
cells, we performed F-actin staining by using Texas Red-X phalloidin
followed by confocal microscopy. Confocal imaging revealed strong
alterations in cell morphology in BT-549 rDOX20/BAG3 KD cells
(Figure 6A), while no obvious morphological changes were found in
the BT-549Par/BAG3 KD cells. BT-549 rDOX20/BAG3 depleted
cells were more rounded and loosely attached, whereas the BAG3-
proficient cells were more flattened, bigger in size and
tightly attached. Similar results were also obtained in MDA-MB-
468 r5-FU2000/BAG3 KD cells (Figure 6B). Western blot analysis
revealed that the increase in FAK phosphorylation at Tyr397 residue
in BT-549 rDOX20cells (Figure 6C) and MDA-MB-468 r5-FU2000
cells (Figure 6D) was reduced after BAG3 knockdown. To further
assess the sensitivity of the BT-549 rDOX20/BAG3 depleted cells to
DOX after matrix detachment, cell adhesion was hindered by coating
the cell culture plates with p-HEMA, so that all cells were cultured in
suspension. Cell death was enhanced in suspension cultures of BAG3-
depleted BT-549 rDOX20 cells after 72 h DOX treatment whereas no
significant changes of cell death were noticed in the BAG3 proficient
BT-549 rDOX20 cells in comparison to controls (Figure 6E).
Depletion of BAG3 Reverses EMT-Associated Expression
Changes in Chemoresistant Breast Cancer Cells
Recently the role of BAG3 in controlling epithelial-mesenchymal
transition (EMT) has come to attention of the scientific community
[19]. To further investigate this phenomenon in chemoresistant cells,
we performed qPCR to analyze the relative mRNA expression levels
of several key genes involved in EMT. qPCR data revealed that
CDH1 (encoding E-cadherin) mRNA expression was strongly
increased whereas CDH2 (encoding N-cadherin) and SNAI1
(encoding Snail) expression was significantly decreased in BAG3-
depleted BT-549 rDOX20 cells (Figure 7A) and MDA-MB-468 r5-
FU2000 cells (Figure 7B), consistent with the hypothesis that BAG3
promotes EMT. We also found reduced mRNA expression of genes
encoding the transcription factors SNAI2 (Snail2), TWIST1 and
TWIST2 in BAG3-depleted BT-549 rDOX20 (Figure S3A) and
similarly in MDA-MB-468 r5-FU2000 cells (Figure S3B). We did not
find any significant changes in the mRNA expression of the above
genes in the parental BAG3-depleted cells compared to their controls,
except the increase of TWIST1 mRNA expression in BAG3-depleted
parental MDA-MB-468 cells (Figure S3B). To further validate our
qPCR data, we performed western blot analysis revealing a strong
up-regulation of E-cadherin and down-regulation of N-cadherin in
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BAG3-depleted MDA-MB-468 r5-FU2000 cells (Figure 7C) which
corroborated our qPCR data. To investigate whether depletion of
BAG3 has any impact on cell invasion and migration properties of the
chemoresistant cells, we performed Boyden-chamber assays and
scratch assays. BAG3-depleted BT-549 rDOX20 cells exhibited
significantly reduced invasiveness compared to the BAG3-proficient
Figure 4. Depletion of BAG3 sensitizes the chemoresistant breast cancer cells by attenuating protective autophagy (A) Stable lentiviral
knockdowns of BAG3 were established in both the BT-549-Par and BT-549rDOX20 cells and (B) also in the MDA-MB-468Par and
MDA-MB-468r5-FU2000 cells. Stable lentiviral transduction of empty vector was used as control (Ctrl). Knockdowns were confirmed by
western blot. Knockdown of BAG3 reduced LC3-II protein expression in BT-549rDOX20 and MDA-MB-468r5-FU2000 cells. GAPDH served
as loading control in western blot. (C) Relative BAG3 mRNA expression was also determined by quantitative PCR (qPCR) after stable
lentiviral knockdowns of BAG3 in BT-549Par and BT-549rDOX20 cell lines and (D) similarly in MDA-MB-468 cells respectively. qPCR data
represent means of three independent experiments± SEM (n = 3). Significant BAG3mRNA expression compared to parental sh Ctrls are
marked by asterisks: * pb0.05, ** pb0.01 and ns not significant. Significant differences between BAG3 KD and respective sh Ctrls are
denoted by hashtags: # pb0.05, ##pb0.01 and ns not significant. (E) Knockdown of BAG3 reduced the protein expression of HSP70,
Mcl-1 and other anti-apoptotic proteins whereas augments the expression of pro-apoptotic proteins like Bak and Bax in BT-549rDOX20
and (F) MDA-MB-468r5-FU2000 cells respectively. GAPDH served as loading control. (G) BT-549rDOX20/BAG3 KD and (H) MDA-MB-468-
r5-FU2000/BAG3 KD cells exhibited significantly higher levels of total cell death compared to their parental counterparts after 72 hours of
DOX and 5-FU treatment in a dose dependent manner respectively. 0.1% DMSO for 72 h was used as control. Cell death was determined
by Annexin V/PI double staining followed by flow cytometry. Data represent means of three independent experiments ± SEM (n = 3).
*pb0.05 and ns not significant of BAG3 KD compared to respective sh Ctrls.
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BT-549 rDOX20 cells after 20 h of incubation (Figure 7D), and
similar results were also obtained in MDA-MB-468 r5-FU2000/BAG3
KD cells (Figure 7E). Our scratch assays also revealed a significantly
reduced motility of BAG3-depleted BT-549 rDOX20 cells (Figure
S4A) and MDA-MB-468 r5-FU2000 cells (Figure S4B) after 20 h
incubation compared to their controls.
Figure 5. HSP70/BAG3 interaction inhibitor YM-1 and HSF-1 inhibitor KRIBB11 sensitize the chemoresistant breast cancer cells (A)
Dissociation of the HSP70/BAG3 complex by YM-1 (5 μM) decreased Mcl-1 expression in BT-549rDOX20 cells after 4 h, 18 h, 24 h, 48 h
treatment inwestern blot analysis. 0.1%DMSO for 48 hwas used asControl (Ctrl) for the solvent, whereas Sorafenib (Sora) 5 μMfor 48 hwas
used as positive control. GAPDHwas used as loading control in western blot. (B) % of cell viability was analyzed byMTT assay in BT-549Par
and BT-549rDOX20 cells after 2 h pre-treatment of 5 μMof YM-1 for 48 h followed by DOX for 72 h. DMSO 0.1% for 48 hwas used as control
(Ctrl) for the solvent. (C) Breast cancer cell lines BT-549Par andBT-549rDOX20were treatedwith 10 ng/ml and 80 ng/ml of DOX for 72 hwith or
without YM-1 (5 μM, 48 h). 0.1%DMSO for 48 hwas used as control (Ctrl) for the solvent. Then cell deathwas analyzed by Annexin-V positive
staining in flow cytometry. Columns represent means of three independent experiments ± SEM (n= 3). Statistical significance: * pb0.05, **
pb0.01, *** pb0.001 and ns not significant compared to ctrls (0.1 % DMSO); # pb0.05, ## pb0.01 and ns not significant with combined
treatment of YM-1 and DOX compared to DOX treatment alone. (D) Combined treatment of KRIBB11 (20 μM, 48 h) and DOX significantly
augment the total cell death in BT-549rDOX20/sh Ctrl cells compared to DOX treatment alone. 0.1%DMSO for 48 hwas used as control (Ctrl)
for the solvent. Cell death was determined by Annexin V/PI double staining followed by flow cytometry. Columns represent means of three
independent experiments ± SEM (n = 3). Statistical significance: * pb0.05, ** pb0.01, *** pb0.001 and ns not significant compared to ctrls
(0.1%DMSO);#pb0.05,##pb0.01andnsnot significantwith combined treatmentof KRIBB11 andDOXcompared toDOX treatment alone.
(E) KRIBB11 treatment decreased BAG3, HSP70, Mcl-1 and LC3 II in a dose dependent manner in BT-549rDOX20 and (F) MDA-MB-468-
r5-FU2000 cells respectively. Cellswere treatedwith 5μM,10μMand20μMofKRIBB11 for 48h.DMSO (0.1%, 48h)was usedascontrol (Ctrl).
GAPDH served as loading control for western blot.
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Proteomic Analysis Reveals a Gene Signature Associated with
Tumor Aggressiveness
The development of drug resistance is a very complex mechanism
including alterations of many different processes and proteins. Thus,
we performed global proteomic analysis of BT-549 rDOX20
compared to BT-549Par using label-free quantification. This analysis
showed that out of the 4906 reproducibly quantified proteins groups,
271 and 307 were significantly under- and overrepresented in
BT-549rDOX20 compared to BT-549Par cells (Figure 8A), respectively.
The 5 most increased and decreased proteins are also depicted in Figure
Figure 6. BAG3 depletion alters cell matrix adhesion in chemoresistant breast cancer cells (A) Knockdown of BAG3 altered cellular
morphology and actin cytoskeletal distribution in BT-549rDOX20 and (B) MDA-MB-468r5-FU2000 cells compared to their respective
parental counterparts in confocal imaging. For staining of F-actin, Texas Red-X phalloidin was used whereas nuclei were stained with
DAPI. Scale bar 10 μm. (C) FAK phosphorylation was reduced in BT-549rDOX20/BAG3 KD and (D) MDA-MB-468r5-FU2000/BAG3 KD cells
respectively. GAPDH served as loading control in the western blot. Densitometric analysis of relative pFAK protein expression was
performed in control and BAG3 KD of both BT-549 andMDA-MB-468 parental and chemoresistant cell lines. Columns represent means ±
SEM. Statistical significance; * pb0.05, ** pb0.01, *** pb0.001 compared to controls (E) BT-549rDOX20/BAG3 KD cells cultured in
suspension exhibited more sensitivity to DOX treatment in a dose dependent manner. Cell cultured dishes were coated with pHEMA to
prevent cell adhesion. Water (0.1%, 72 h) was used as control (Ctrl) for the solvent. Cell death was determined by Annexin V/PI double
staining followed by flow cytometry. Columns represent means of three independent experiments performed in triplicate ± SEM.
Statistical significance: * pb0.05, ** pb0.01, *** pb0.001 and ns not significant compared to ctrls (0.1 % water); # pb0.05 and ns not
significant with combined treatment of DOX and pHEMA compared to DOX treatment alone.
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8A, the complete list of significantly changed proteins is provided as a
supplemental file (Table S1). Bioinformatics analysis using the freely
available STRING-platform (string-db.org); [41] was carried to analyze
Gene Ontology (GO) terms that were significantly enriched among the
reduced or increased proteins (Figure 8A). In total 20 and 27 KEGG
pathways were significantly overrepresented among reduced and
increased protein groups respectively (Figure 8B). Reduced pathways
include focal adhesion and cell adhesion molecules (CAMs). Increased
pathways include citrate cycle (TCA) and oxidative phosphorylation, two
metabolic pathways that are correlated with tumor aggressiveness [42],
but also DNA replication and cell cycle, indicating increased
proliferation. The analyses of biological processes (GO:BP; Figure 8C)
Figure 7. Knockdown of BAG3 reverses the EMT phenomena and simultaneously suppresses invasion in chemoresistant breast cancer
cells (A) Knockdown of BAG3 reduced the relative CDH2, SNAI1mRNA expression, simultaneously increased CDH1mRNA expression in
BT-549rDOX20/BAG3 KD and (B) MDA-MB-468r5-FU2000/BAG3 KD cells in qPCR respectively. qPCR data represent means of three
independent experiments ± SEM (n = 3). Significant mRNA expression compared to parental sh Ctrls are marked by asterisks: * pb0.05,
** pb0.01 and ns not significant. Significant differences between BAG3 KD and respective sh Ctrls are denoted by hashtags: # pb0.05, ##
pb0.01 and ns not significant. (C) Expression of E-cadherin protein was increased whereas N-cadherin expression was decreased in
MDA-MB-468r5-FU2000/BAG3 KD cells in western blot. GAPDH served as loading control. (D) Number of invaded cells was decreased in
BT-549rDOX20/BAG3 KD and (E) MDA-MB-468r5-FU2000/BAG3 KD cells. Invasion assay was performed for 20 h followed by stained with
1% crystal violet, bright field image was taken and invaded cells were counted by using ImageJ software. Columns represent means of
three independent experiments ± SEM (n = 3). Statistical significance of invasion: ** pb0.01, *** pb0.001 and ns not significant with
BAG3 KD compared to sh Ctrls.
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revealed that among the top 10 processes which were overrepresented
among the reduced proteins, extracellular matrix organization
(GO.0030198) and response to stress (GO.0006950) are the highest
ranking processes. Notably, other processes whose associated proteins
were significantly enriched are related to regulation of apoptosis (e.g.:
regulation of extrinsic apoptotic signaling pathway (GO.2001236) and
regulation of apoptotic signaling pathway (GO.2001233)) and cell
adhesion (e.g.: positive regulation of cell adhesion (GO.0045785) and
cell-cell adhesion mediated by integrin (GO.0033631)). On the other
hand many increased processes are related to an enhanced metabolism,
including cellular amino acid metabolic process (GO.0006520), cellular
metabolic process (GO.0044237) and also cellular respiration
(GO.0045333). Other processes are related to an increased glucose
and ATP metabolism (e.g.: gluconeogenesis (GO.0006094), ATP
metabolic process (GO.0046034)), replication (DNA strand elongation
involved in DNA replication (GO.0006271)). Basically, each of the 10
most increased and decreased single proteins found have previously
been related to tumorigenesis or tumor progression (Table 2), thus
exemplifying that treatment resistance is accompanied by a more
aggressive phenotype.
Discussion
Here we demonstrate that overexpression of BAG3 is associated with
chemotherapy resistance of triple negative BT-549 and MDA-MB-
468 breast cancer cells that were adapted to growth in the presence of
the clinically applied chemotherapeutic agents 5-FU, DOX and
DOC. Furthermore, we provide evidence that the increased apoptosis
resistance of these cells is associated with BAG3-dependent
stabilization of the pro-survival Bcl-2 family proteins Bcl-2, Bcl-xL
and Mcl-1, induction of EMT-like transcriptional changes and
enhanced cytoprotective autophagy that partially contributes to
increased cell survival. In line with our findings, overexpression of
BAG3 has been reported in several types of human cancers, such as
glioblastoma [21], lung carcinoma [43], pancreatic carcinoma [44],
Figure 8. Proteomic analysis reveals a gene signature associated with tumor aggressiveness in BT-549rDOX20 cells (A) Volcano-Plot
showing the protein ratios (in log2) as a function of the –log p-value of label-free quantification proteomic-data from BT-549rDOX20 cells
compared to BT-459Par. A total of 4906 proteins were quantified, of those 271 (red dots) and 307 (blue dots) were significantly reduced
and increased, respectively. (B and C) Bioinformatic cluster analysis using String (string-db.org; [41]) was performed. (B) Shows all KEGG
pathways that are overrepresented among reduced (red) or increased protein groups (blue). (C) Shows the 10 highest ranking Gene
Ontology (GO) biological processes (GO:BP) that are overrepresented among proteins with significantly reduced (red) or increased
amount (blue).
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leukemia [45], and thyroid carcinoma [46], compared with very low
basal levels of BAG3 in non-malignant cells [43]. Consistent with the
hypothesis that BAG3 may represent a key resistance factor in breast
cancer; a very recent study demonstrated that enhanced BAG3
expression correlates with poor patient survival in this tumor entity [47].
All drug-adapted BT-549 and MDA-MB-468 cell lines displayed
cross resistance to chemotherapy and the apoptosis inducer STS,
indicating an increase in general apoptosis resistance. BAG3
expression was visibly elevated in all three resistant MDA-MB-468
lines and one of the BT-549 lines. To further address the role of
BAG3 in cell death resistance, we performed stable lentiviral BAG3
depletion in the BT-549 rDOX20 and MDA-MB-468 r5-FU2000 cell
lines. Interestingly, BAG3 depletion led to a robust down-regulation
of Mcl-1, Bcl-2 and Bcl-xL and apoptosis was efficiently restored
exemplifying its crucial role in apoptosis resistance.
The levels of the autophagy markers LC3-II, ATG5 and Beclin-1
were also found to be elevated in BT-549 rDOX 20 and
MDA-MB-468 r5-FU2000 cells. In our chemoresistant cell models,
expression of both Bcl-2 and Beclin-1 was elevated simultaneously,
suggesting that interaction of Bcl-2 and Beclin-1 may have no
significant effect on the regulation of autophagy in these cells. This
notion is consistent with previously reported findings pointing to an
indirect effect of Bcl-2 on autophagy that is mediated by inhibiting
Bak and Bax [48]. Since pro-survival autophagy is a key mechanism
underlying drug resistance of cancer cells in many paradigms [35], we
investigated the potential contribution of cytoprotective autophagy in
chemotherapy resistance. To this end, we applied the pharmacological
autophagy inhibitor Baf A1 and established stable lentiviral
knockdowns of ATG5 to block the non-selective macroautophagy
pathway. In our experiments, treatment with Baf A1 and knockdown
of ATG5 significantly increased apoptotic cell death after treatment
with DOX and 5-FU in BT-549 rDOX 20 and MDA-MB-
468 r5-FU2000 resistant cells respectively, but not in parental cells,
indicating that enhanced autophagy may indeed partially contribute
to drug resistance.
In a similar fashion, lentiviral knockdown of BAG3 significantly
resensitized both resistant cell lines to drug treatment, indicating that
BAG3 overexpression is involved in acquired drug resistance. Interest-
ingly, BAG3 depletion was associated with decreased levels of both LC3-I
and LC3-II, indicating that BAG3 overexpression may contribute to
enhanced autophagy in the resistant setting. Of note, BAG3 was
previously shown to regulate total LC3 levels at the translational level,
possibly leading to enhanced basal autophagy [49]. We also found that
depletion of BAG3 in chemoresistant cells facilitates the translocation of
BAX to mitochondria suggesting that BAG3-dependent sequestration of
BAX in the cytoplasmic compartment [21] may contribute to the
anti-apoptotic effects of BAG3 in breast cancer chemoresistant cells.
In order to overcome the proposed BAG3-driven resistance, we
also pharmacologically targeted the BAG3/HSP70/Mcl-1 signaling
axis. The BAG3 gene is a transcriptional target of the stress-induced
transcription factor HSF1. KRIBB11 was found to selectively inhibit
the transcriptional activity of HSF1 [50], which is required for expression
of both BAG3 and its interactor HSP70. Indeed, we could observe
significant synergistic effects on cell death in the combination therapy
with KRIBB11 and DOX in the BT-549rDOX20 cell line. To further
scrutinize these pro-apoptotic effects of BAG3 inhibition, we employed
the specific HSP70/BAG3 small molecule inhibitor YM-1 that prevents
formation and function of the HSP70-BAG3module [39]. Inhibition of
BAG3 by YM-1 significantly decreased the protein levels of Mcl-1 and
was able to mimic the sensitizing effect of BAG3 depletion on apoptosis
after combined treatment with DOX in BT-549rDOX20 cells. These
data underscore the pivotal role of the HSP70 interaction in promoting
the anti-apoptotic function of BAG3 and highlight the relevance of this
complex as a therapeutic target in breast cancer.
Global proteomic analysis of BT-549rDOX20 revealed major changes
in several pathways/biological processes implicated in tumorigenesis and
tumor progression, including cell adhesion. Besides its anti-apoptotic
function, BAG3 was also suggested to support cell adhesion and motility
[40], and to mediate resistance to anoikis, a special form of apoptosis
induced by matrix detachment [27]. The ability of BAG3 to regulate cell
Table 2. The 10 Highest Ranking Proteins are Listed Along with the NCBI Gene ID, the Log2 Ratio of BT-549rDOX20Over BT-549Par and the –Log P Value, as Well as a Brief Summary of the Known
Function of These Proteins in Cancer
Official gene name Gene-ID log2 ratio –log p value Function
ANPEP 290 -8.567 3.364 Silenced in prostate cancer [53]
LRP1 4035 -7.233 3.030 Cancer cell survival and metastasis [54]
DCLK1 9201 -6.092 3.274 Associated with favorable prognosis in breast cancer [55]
COL5A1 1289 -5.178 4.235 Marker gene for TNBC classification [56]
OAS2 4939 -4.594 2.313 Higher expression in relapsed tumors [57]
STEAP3 55240 -4.294 2.433 Part of a metastasis gene signature [58]
PLA2G4A 5321 -4.190 2.565 Associated with adverse prognosis [59]
ITPR1 3708 -3.948 3.958 Breast cancer susceptibility locus [60] [61]
SERPINB5 5268 -3.900 3.477 Tumor suppressor in breast cancer [62]
DTX3L 151636 -3.881 2.156 Associated with overall survival and autophagy signature [63]
Official gene name Gene-ID log2 ratio –log p value Known relevance for breast cancer
EDIL3 10085 6.668 3.885 Cell invasion and metastasis [64]
ALDH5A1 7915 5.188 2.805 Stem-like phenotype [65]; detoxifaction [66]
MYO6 4646 4.908 3.694 Oncogenic in breast cancer [67]
FHL2 2274 4.317 3.774 Oncogenesis and tumor progression [68,69]
CROT 54677 4.242 2.945 Correlates with drug resistance [70]
LMCD1 29995 4.101 2.864 Involved in tumor recurrence [71]
GNG11 2791 4.049 3.740 Cell migration and metastasis [72]
KYNU 8942 3.908 1.968 Metastasis [73]
CUX1 1523 3.804 4.027 Migration, invasion and apoptosis-resistance [74,75]
TAGLN 6876 3.349 2.201 Epithelial mesenchymal transition [76]
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adhesion was proposed to rely on multiple interactors (e.g. PDZGEF2
andCCN1) of BAG3 through different structural domains in this context
[51]. Moreover, BAG3 was implicated in cytoskeleton organization by
regulating actin folding via interaction with CCT, a cytosolic chaperonin
[52]. The important role of BAG3 in cytoskeleton organization was also
observed in this study, as demonstrated by gross re-arrangements of the
cytoskeletal structure in BAG3-depleted cells that was visualized by actin
staining followed by confocal microscopy. In particular, BAG3 depletion
was accompanied with a more rounded and loosely attached cellular
morphology. A role of BAG3 in controlling epithelial-mesenchymal
transition (EMT) was recently proposed [19]. Indeed, we observed an
EMT-like expressional shift in chemotherapy-resistant cells compared to
parental controls in our cell models. This shift was associated with
increased expression of CDH2 (N-cadherin), SNAI1 (Snail1), SNAI2
(Snail2), TWIST1 and TWIST2 and decreased expression of CDH1
(E-cadherin). Consistent with the proposed function of BAG3 in EMT
modulation, BAG3 depletion induced a back shift in the expression
pattern of these genes to a more epithelial like state and also reduced the
invasiveness and motility in the resistant cell models.
Our findings obtained in established cell lines and their drug-resistant
derivatives represent a first step in elucidating specific mechanisms of
acquired therapy resistance. These data open the avenue for follow-up
investigations in patient-derived cultures and in vivomodels. Collectively,
we demonstrate that BAG3 plays a major role for the cell death resistance
of breast cancer cells and their response to chemotherapy, as well as their
aggressive growth characteristics. Based on the findings of our study, we
propose that by stabilizing anti-apoptotic Bcl-2 family members and
promoting EMT-like changes, the HSF1/HSP70/BAG3 pathway may
play a pivotal role for therapy resistance of breast cancer. Pharmacological
intervention with BAG3 and HSP70 function is an interesting approach
for combined therapies aimed at synergistically inducing apoptosis in
advanced breast cancer and may aid the design of new strategies aimed at
overcoming the resistance to current breast cancer therapy.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.01.001.
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